Anavex Life Sciences Corp. (AVXL)

3.73
0.10 2.61
NASDAQ
Prev Close 3.83
Open 3.78
Day Low/High 3.52 / 3.82
52 Wk Low/High 2.50 / 14.84
Volume 765.01K
Exchange NASDAQ
Shares Outstanding 35.71B
Market Cap 135.70M
Div & Yield N.A. (N.A)

Latest News

Gold, Utilities, Bonds Post Gains

I stopped out of Lantheus Holdings for a small loss and bought Baozun near $15.

Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results As An Analgesic In Animal Models Of Neuropathic And Visceral Pain

Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results As An Analgesic In Animal Models Of Neuropathic And Visceral Pain

Preclinical Data for ANAVEX 1066 Presented at Society for Neuroscience Annual Meeting

Short Interest In Anavex Life Sciences Increases 18.6%

Short Interest In Anavex Life Sciences Increases 18.6%

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 883,721 share increase in total short interest for Anavex Life Sciences Corp , to 5,641,528, an increase of 18.57% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

5 Stocks Under $10 Poised for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades. Here's how to trade them from here.

4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid

4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Anavex (AVXL) Stock Soars on Parkinson's Drug Success

Anavex (AVXL) Stock Soars on Parkinson's Drug Success

Anavex (AVXL) announced on Thursday its Anavex 2-73 Parkinson's treatment was successful in a preclinical study.

Anavex Life Sciences' Drug Shows Efficacy To Support Potential Disease Modification In Parkinson's Disease

Anavex Life Sciences' Drug Shows Efficacy To Support Potential Disease Modification In Parkinson's Disease

Michael J. Fox Foundation funded ANAVEX 2-73 drug candidate study presented at World Parkinson Congress 2016

Anavex To Participate In Mizuho Therapeutics Conference

Anavex To Participate In Mizuho Therapeutics Conference

Conference to Feature Companies with Focus on Alzheimer's, Parkinson's and other Neurological Diseases

Noteworthy Wednesday Option Activity: AVXL, CRUS, ASPS

Noteworthy Wednesday Option Activity: AVXL, CRUS, ASPS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anavex Life Sciences Corp , where a total volume of 10,707 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 90.4% of AVXL's average daily trading volume over the past month, of 1.2 million shares.

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.

Notable Friday Option Activity: AVXL, WNR, RLYP

Notable Friday Option Activity: AVXL, WNR, RLYP

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Anavex Life Sciences Corp , where a total of 3,227 contracts have traded so far, representing approximately 322,700 underlying shares. That amounts to about 41.6% of AVXL's average daily trading volume over the past month of 776,365 shares.

These 5 Stocks Are Ready to Break Out Now

These 5 Stocks Are Ready to Break Out Now

These stocks look ready to break out and trade higher from current levels.

Anavex Announces Positive Preclinical Results With ANAVEX 2-73 In Fragile X - Autism-Related Disorders

Anavex Announces Positive Preclinical Results With ANAVEX 2-73 In Fragile X - Autism-Related Disorders

Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders

Anavex Announces Positive Preclinical Data For ANAVEX 2-73 In Infantile Spasms

Anavex Announces Positive Preclinical Data For ANAVEX 2-73 In Infantile Spasms

Detailed Data to be Presented at Upcoming Scientific Meeting